Literature DB >> 22593633

Belimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus.

Raymond Lamore, Sapna Parmar, Khilna Patel, Olga Hilas.   

Abstract

Entities:  

Year:  2012        PMID： 22593633      PMCID： PMC3351861     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  8 in total

1.  Classification and definition of major flares in SLE clinical trials.

Authors:  M Petri; J Buyon; M Kim
Journal:  Lupus       Date:  1999       Impact factor: 2.911

2.  From BILAG to BLIPS--disease activity assessment in lupus past, present and future.

Authors:  D A Isenberg; C Gordon
Journal:  Lupus       Date:  2000       Impact factor: 2.911

Review 3.  Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.

Authors:  Bridget Griffiths; Marta Mosca; Caroline Gordon
Journal:  Best Pract Res Clin Rheumatol       Date:  2005-10       Impact factor: 4.098

Review 4.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

Review 5.  Assessment of systemic lupus erythematosus.

Authors:  G K W Lam; M Petri
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

6.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

7.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01

8.  Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.

Authors:  Richard Furie; William Stohl; Ellen M Ginzler; Michael Becker; Nilamadhab Mishra; Winn Chatham; Joan T Merrill; Arthur Weinstein; W Joseph McCune; John Zhong; Wendy Cai; William Freimuth
Journal:  Arthritis Res Ther       Date:  2008-09-11       Impact factor: 5.156
  8 in total
  7 in total

1.  Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries.

Authors:  Katherine A Owen; Andrew Price; Hannah Ainsworth; Bryce N Aidukaitis; Prathyusha Bachali; Michelle D Catalina; James M Dittman; Timothy D Howard; Kathryn M Kingsmore; Adam C Labonte; Miranda C Marion; Robert D Robl; Kip D Zimmerman; Carl D Langefeld; Amrie C Grammer; Peter E Lipsky
Journal:  Am J Hum Genet       Date:  2020-10-07       Impact factor: 11.025

Review 2.  Lupus, Silica, and Dietary Omega-3 Fatty Acid Interventions.

Authors:  Kathryn A Wierenga; Jack R Harkema; James J Pestka
Journal:  Toxicol Pathol       Date:  2019-11-14       Impact factor: 1.902

Review 3.  Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis.

Authors:  J D Kleinke; Nancy McGee
Journal:  Am Health Drug Benefits       Date:  2015-05

4.  Identification of polo-like kinase 1 as a therapeutic target in murine lupus.

Authors:  Yaxi Li; Hongting Wang; Zijing Zhang; Chenling Tang; Xinjin Zhou; Chandra Mohan; Tianfu Wu
Journal:  Clin Transl Immunology       Date:  2022-01-06

Review 5.  Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Authors:  Hamideh Raeisi; Masoumeh Azimirad; Ali Nabavi-Rad; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

6.  Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program.

Authors:  Deeba Minhas; Wendy Marder; Sioban Harlow; Afton L Hassett; Suzanna M Zick; Caroline Gordon; Kamil E Barbour; Charles G Helmick; Lu Wang; Jiha Lee; Amrita Padda; W Joseph McCune; Emily C Somers
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-24       Impact factor: 5.178

7.  Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.

Authors:  WeiYu Lin; Dhaya Seshasayee; Wyne P Lee; Patrick Caplazi; Sami McVay; Eric Suto; Allen Nguyen; Zhonghua Lin; Yonglian Sun; Laura DeForge; Mercedesz Balazs; Flavius Martin; Ali A Zarrin
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.